Miriam Moscovitch-Lopatin, from MassGeneral Institute for Neurodegenerative Disease presented a longitudinal pre-cell biomarker study she conducted on an ultrasensitive Simoa immunoassay for quantifying BDNF levels in cerebral spinal fluid in early Huntington's disease at the inaugural Powering P
Alison Joyce from Pfizer, Inc. presented her research on the development of a sensitive homebrew Simoa assay to detect Leucine-rich repeat Kinase 2 (LRRK2) at the inaugural Powering Precision Health Summit 2016.
Jessica Gill, PhD, RN, from the National Institute of Health, presented her research on the role of proteomic biomarkers of brain injuries at the inaugural Powering Precision Health Summit 2016.
Danielle Graham, PhD from Biogen presented on accelerating exploratory fluid biomarker assay development in neurodegenerative disease at the inaugural Powering Precision Health Summit 2016.
Cheryl Wellington, PhD from the University of British Columbia, presented on the functional modeling of the human cerebrovasculature at the inaugural Powering Precision Health Summit 2016.
Rama Boyanapalli, PhD from Shire Pharmaceuticals presented novel research on the long and winding road to a highly sensitive RANKL Assay at the inaugural Powering Precision Health Summit 2016.
John Yan, PhD, from Takeda Pharmaceutical Company presented an ultrasensitive assay format for detecting PD biomarkers in cell and xenograft tumors at the inaugural Powering Precision Health Summit 2016.
Ralph McDade, PhD from Myriad RBM presented a triphase approach to biomarker pattern discovery for cancer immunotherapy and autoimmune disease at the inaugural Powering Precision Health Summit 2016.
This webinar describes a groundbreaking new technique published recently in Analytical Chemistry for measuring single cancer cells. The study, conducted by Dr. David Walt and his research group at Tufts University, demonstrates that the ultrasensitive Simoa technology makes it possible to quantify…
